Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
about
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapyEpigenetic treatment of solid tumours: a review of clinical trialsNew strategies in lung cancer: epigenetic therapy for non-small cell lung cancerCarboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerRepositioning approved drugs for the treatment of problematic cancers using a screening approach.Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.Vorinostat in solid and hematologic malignanciesPhase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II studyPhase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaUpdates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology.Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinicImmunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer.A pharmacogenomic method for individualized prediction of drug sensitivitySquamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.New molecular targeted therapies for advanced non-small-cell lung cancer.Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.Clinical efficacy of vorinostat in a patient with leiomyosarcoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerCarfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agentsEpigenetic therapy in lung cancer.Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.The epigenome as a potential mediator of cancer and disease prevention in prenatal development.Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerCombined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesEssential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.Epigenetics in cancer stem cells.HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.Promises and challenges of anticancer drugs that target the epigenome.Emerging new agents for the management of patients with non-small cell lung cancer.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer.Histone deacetylase inhibitors in hematological malignancies and solid tumors.
P2860
Q24609974-24447EDE-F418-47DC-932A-B1918709C5B4Q26773803-BB6DFA48-2828-4B0B-85D2-11E7BD7925D9Q28236190-4519BDFC-9CBB-4F79-A48F-1AAAB6423F32Q28265589-7223AA64-5551-44B6-95DB-DE1E6E8B576BQ29248487-5426A9F2-06D6-42B9-B799-C302ABD2A8F6Q30430515-30E0AA38-886F-4AA4-A504-691B393CF09DQ33385544-4B1E1F87-E781-4857-9A8C-B1C2AF5C950BQ33391851-4FD9BB8A-DDAF-413E-A8A0-704DD2CA821BQ33408143-3DD5D9EC-B645-4CE3-8678-3CA1A748FCE1Q33420546-D80DEE83-B834-4FC4-9CD0-31BB93A3760BQ33875268-47E5D4DE-6BBB-4814-9E71-302C510A3821Q34371189-BF9338CA-E2DA-49E9-8900-8D66B72D1328Q35038016-E6C61EAA-284B-4047-8C17-BEECCA65A7F4Q35078816-E140A51F-10D0-4FA7-AD7F-987BDAD417CEQ35176386-29B27394-10D8-4433-9A48-29B5D87AF511Q35220347-48494AAC-309F-4A24-8E72-864E8AA97782Q35667806-7A92B2C9-2C9C-4F8E-9327-6FD208057190Q35686880-A4FDCB44-4AD1-4103-868F-47D83265F588Q35789686-E483DB4F-556C-447B-8481-326A1B296FF2Q35939690-93BA040E-CE00-4517-880C-10FAC0F7274EQ36301182-53567926-86CC-4C85-BB7F-DBD3A56C439EQ36578084-3C0E3F9B-3D21-4944-9D6E-E3067D220AF1Q36645808-20635337-FDBD-4AF3-8B3F-516CE41AE55AQ36885903-65B8C10F-2B8A-411D-9D10-F04620B7E187Q36895363-87DCBDEE-29B9-4BC1-B75F-B7E8EFA081D5Q36990438-F23E0E6C-717C-47A8-8367-D9863EF6A20EQ37093273-5404EEFC-5CBC-47F6-95C4-B95CA52DBF4CQ37098331-7F69E692-A4CC-4256-88E7-96C72A8DD0F1Q37226511-BA410749-E64D-4ADB-AACF-AB31EC249664Q37348159-B78CCBB7-F956-4565-966F-06C783ED13D0Q37421431-D2379EE1-DC96-4E07-8CF9-094469E86BD0Q37512730-8479A67F-92B1-449B-A8C0-562E7E17C3C8Q37618640-F961B1CB-0F4D-4533-9CC7-B3579C36DEC8Q37949185-1D9AED08-F0C1-480C-8890-7637528F1A1BQ37962596-FCA39075-4028-4F18-B0E3-4C4AB57BD4C6Q38019977-474AF75C-D72C-4582-893B-0B92CBC389BAQ38081988-A46EFC3E-2738-4BDB-A82D-8DF3A4594EBBQ38121995-74858740-DAC8-46B1-B380-9ADCC728FB03Q38140920-FD6BEE72-B5B1-47A0-B662-23B02353DAFCQ38344675-550AA00A-3C21-4094-A329-6C6B4854510C
P2860
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Vorinostat (NSC# 701852) in pa ...... cology Network phase II study.
@ast
Vorinostat (NSC# 701852) in pa ...... cology Network phase II study.
@en
Vorinostat
@nl
type
label
Vorinostat (NSC# 701852) in pa ...... cology Network phase II study.
@ast
Vorinostat (NSC# 701852) in pa ...... cology Network phase II study.
@en
Vorinostat
@nl
prefLabel
Vorinostat (NSC# 701852) in pa ...... cology Network phase II study.
@ast
Vorinostat (NSC# 701852) in pa ...... cology Network phase II study.
@en
Vorinostat
@nl
P2093
P2860
P1476
Vorinostat (NSC# 701852) in pa ...... cology Network phase II study.
@en
P2093
Anne M Traynor
Courtney M Hallahan
David L Groteluschen
Hilary R Weeks
Igor Espinoza-Delgado
Jens C Eickhoff
Jill M Kolesar
Joan H Schiller
Kathleen Schell
Michael S Huie
P2860
P304
P356
10.1097/JTO.0B013E3181952478
P577
2009-04-01T00:00:00Z